Recruiting

New drug combination versus chemotherapy for resistant Hodgkin lymphoma

Plain-English translation of NCT06170489 on ClinicalTrials.gov ↗ · Source last updated February 2025 · Translation generated June 2026 · How we translate trials

Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.

What is this trial?

This trial is testing whether JS004 combined with Toripalimab—two medications that work together to help your immune system fight cancer—can treat Hodgkin lymphoma better than standard chemotherapy drugs. You would be randomly assigned to receive either this new medication combination or one of two traditional chemotherapy options. The study wants to see if the medication combination is safer and more effective for people whose lymphoma has stopped responding to previous immunotherapy.

Hodgkin lymphoma can sometimes stop responding to the most common immunotherapy treatments available today, leaving patients with limited options. Researchers believe this new medication combination might help people in this difficult situation by attacking the cancer in a different way.

Do you qualify?

You likely qualify if…

you are at least 18 years old
you have been diagnosed with classical Hodgkin lymphoma that has either relapsed (come back after initial treatment) or never responded to initial treatment
your lymphoma has already stopped responding to prior immunotherapy (PD-L1 inhibitor) treatments and you have exhausted standard options
you have a measurable tumor that can be tracked on imaging scans
you are in reasonably good overall health (ECOG performance status 0-2)

You likely don't qualify if…

you have had a serious allergic reaction to either of these medications or their components
you previously had to stop immunotherapy treatment because of severe immune-related side effects
you have cancer that has spread to your brain or central nervous system
you have fluid buildup around your lungs, abdomen, or heart that requires medical drainage
you have an active autoimmune disease that currently requires treatment with steroids or immunosuppressive medications

What participation looks like

If you enroll, you'll be randomly assigned to either receive the new medication combination or standard chemotherapy. If assigned to the new treatment, you would receive two intravenous (IV) infusions every 3 weeks for up to 2 years. The study involves multiple clinic visits for monitoring, blood work, and imaging scans to see how well the treatment is working and to track any side effects. Your doctor and the research team will closely follow your health throughout the trial.

AI-generated summary from trial data · Jun 12, 2026 · Not medical advice

Trial locations(1 site)

China

Beijing Cancer Hospital, Beijing, Beijing Municipality